Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Recent health news includes Pfizer settling a lawsuit about a diversity fellowship, a New York doctor indicted for prescribing abortion pills in Louisiana, AstraZeneca canceling UK investment, ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Recent health news covers significant events like Pfizer's diversity program settlement, AstraZeneca's halted UK investment, ...

Trump imposed 25% tariffs on imports from Mexico and Canada and 10% on China. Major earnings reports this week include Amazon ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials Individual patient data of neoadjuvant RCTs ...

Select listed pharmaceuticals companies including Pfizer Ltd, Novartis India Ltd, AstraZeneca Pharma India Ltd and GSK Pharmaceuticals Ltd shall be the beneficiaries of the budget announcements ...